STOCK TITAN

STANDARD BIOTOOLS (NASDAQ: LAB) director receives new RSU and stock option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

STANDARD BIOTOOLS INC. director Kathy L. Hibbs reported equity awards that increase her stake in the company. On June 18, 2026, she received 99,116 shares of Common Stock as Restricted Stock Units that vest in full on the earlier of June 18, 2027 and one day prior to the next annual stockholders’ meeting, subject to continued service.

She also received a stock option for 175,923 shares of Common Stock at an exercise price of $0.8297 per share, becoming exercisable in twelve equal monthly installments beginning on July 18, 2026, also subject to continued service. After these awards, she directly owns 236,836 shares plus 175,923 stock options.

Positive

  • None.

Negative

  • None.
Insider HIBBS KATHY L
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to buy) 175,923 $0.00 --
Grant/Award Common Stock 99,116 $0.00 --
Holdings After Transaction: Stock Option (Right to buy) — 175,923 shares (Direct, null); Common Stock — 236,836 shares (Direct, null)
Footnotes (1)
  1. Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
RSU grant size 99,116 shares Restricted Stock Units vesting by June 18, 2027 or before next annual meeting
Option grant size 175,923 options Stock Option (Right to buy) granted June 18, 2026
Option exercise price $0.8297 per share Exercise price for 175,923 stock options
Shares after award 236,836 shares Total Common Stock directly owned after RSU grant
Underlying option shares 175,923 shares Common Stock underlying stock option award
Option expiration June 18, 2036 Expiration date of stock option grant
RSU vesting reference date June 18, 2027 Latest vesting date for RSUs, subject to earlier annual meeting trigger
Restricted Stock Units ("RSUs") financial
"Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027..."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to buy) financial
"Stock Option (Right to buy) with 175,923.0000 shares and an exercise price of 0.8297..."
exercise price financial
"conversion_or_exercise_price: "0.8297" for the Stock Option (Right to buy)..."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"RSUs vest in full on the earlier of June 18, 2027 and one day prior to the next annual meeting, subject to continued service..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: "2036-06-18T00:00:00.000Z" for the stock option award..."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HIBBS KATHY L

(Last)(First)(Middle)
C/O STANDARD BIOTOOLS INC.
50 MILK STREET, 10TH FLOOR

(Street)
BOSTON MASSACHUSETTS 02109

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/18/2026A99,116(1)A$0236,836D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to buy)$0.829706/18/2026A175,923 (2)06/18/2036Common Stock175,923$0175,923D
Explanation of Responses:
1. Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
2. The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
/s/ Kathy L. Hibbs by Tomone Tanaka, Attorney-in-Fact06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did STANDARD BIOTOOLS (LAB) director Kathy Hibbs receive in this Form 4?

Kathy Hibbs received stock-based compensation awards, including 99,116 Restricted Stock Units and options for 175,923 shares. These awards increase her direct equity exposure to STANDARD BIOTOOLS, aligning her interests more closely with shareholders through future-vesting stock and stock options.

How many STANDARD BIOTOOLS (LAB) shares does Kathy Hibbs hold after this filing?

After the awards, Hibbs holds 236,836 shares of STANDARD BIOTOOLS Common Stock directly, plus options for 175,923 additional shares. This reflects her total reported direct ownership position immediately following the June 18, 2026 compensation grants.

What are the terms of Kathy Hibbs’ RSU grant at STANDARD BIOTOOLS (LAB)?

The RSU grant covers 99,116 shares that vest in full on the earlier of June 18, 2027 and one day before the next annual stockholders’ meeting, if she remains in service. Each RSU converts into one share of common stock upon vesting.

What are the key details of Kathy Hibbs’ new stock options at STANDARD BIOTOOLS (LAB)?

Hibbs received options on 175,923 shares at $0.8297 per share. These options begin vesting in twelve equal monthly installments starting July 18, 2026, contingent on her continued service, and expire on June 18, 2036 if not exercised.

Does this STANDARD BIOTOOLS (LAB) Form 4 show an insider stock sale?

No, the Form 4 reports equity grants, not open-market sales. All transactions are coded as awards (code A), reflecting compensation-related acquisitions of RSUs and stock options rather than purchases or sales in the market.

How might these equity awards affect STANDARD BIOTOOLS (LAB) shareholders?

The awards modestly increase potential future share count through 99,116 RSUs and 175,923 option shares. They also strengthen incentive alignment, as a director’s compensation is tied to future company performance via vesting schedules and an option exercise price.